Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$8.38 USD
+0.33 (4.10%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.38 USD
+0.33 (4.10%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Amneal (AMRX) Down on Guidance Update & Restructuring Plan
by Zacks Equity Research
Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.
Amneal Pharmaceuticals (AMRX) Misses Q1 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down
by Zacks Equity Research
A U.S. appeals court declines J&J's (JNJ) request to prevent the launch of generic versions of Zytiga. Stock down more than 3%.
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.
Lannett Set to Lose Distribution Agreement With Key Supplier
by Zacks Equity Research
Lannett Company's (LCI) distribution agreement with key supplier, Jerome Stevens Pharmaceuticals, not to be renewed on expiry. Shares plunge.
Company News For Aug 21, 2018
by Zacks Equity Research
Companies In The News are: EL,COP,PX,AMRX
Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 4.35% and -0.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?